Publications by authors named "Andrea Acerbis"
Article Synopsis
- Invasive fungal infections (IFIs) are a significant health issue for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), and Isavuconazole (ISA) is a safe antifungal treatment option being studied in combination with sirolimus.
- This retrospective analysis looked at 51 allo-HSCT patients treated with both ISA and sirolimus over about five years, focusing on the effectiveness, safety, and monitoring of drug levels.
- Results showed that ISA was effective in treating IFIs, with a 68% response rate after 90 days, and no significant drug interaction toxicities were reported when both drugs were administered at therapeutic levels.
Leukemia relapse is a major cause of death after allogeneic hematopoietic cell transplantation (allo-HCT). We tested the potential of targeting T cell (Tc) immunoglobulin and mucin-containing molecule 3 (TIM-3) for improving graft-versus-leukemia (GVL) effects. We observed differential expression of TIM-3 ligands when hematopoietic stem cells overexpressed certain oncogenic-driver mutations.
View Article and Find Full Text PDFArticle Synopsis
- Invasive fungal diseases (IFDs) are a significant cause of mortality in patients with hematological conditions like AML and MDS, particularly during chemotherapy and after stem cell transplants.
- Mold-active antifungal prophylaxis (MAP) is the standard care, though breakthrough infections (b-IFDs) like invasive aspergillosis remain a pressing issue.
- A study of 184 AML/MDS patients showed a 1.7% incidence of b-IFDs while undergoing high-dose chemotherapy with posaconazole, highlighting ongoing challenges in diagnosis and treatment adaptations in a rapidly changing medical landscape.
Cytomegalovirus (CMV) reactivations are strong stimulators of immune-reconstitution (IR) in hematopoietic stem cell transplantation (HSCT) recipients. Herein, we analyzed 317 CMV-seropositive consecutive patients (n = 109 letermovir, LTV; n = 208 no-LTV), undergoing HSCT with post-transplant cyclophosphamide (PTCy) and calcineurin inhibitor- (CNI) free graft-versus-host-disease (GvHD) prophylaxis. At day+90, median CD19/mm was higher in LTV-cohort: 5.
View Article and Find Full Text PDFAllogeneic hematopoietic stem cell transplantation (allo-HSCT) in SARS-CoV-2 positive candidates is usually delayed until the clinical resolution of the infection's symptoms and a negative nasopharyngeal molecular test. However, prolonged SARS-CoV-2 positivity has been frequently observed in haematological malignancies, thus representing a challenge for the timing of transplant procedures. Here, we report on the case of a 34-year-old patient with recent pauci-symptomatic COVID-19 undergoing transplant for high-risk acute B-lymphoblastic leukemia before achieving viral clearance.
View Article and Find Full Text PDFArticle Synopsis
- A 59-year-old woman had serious problems with her organs after getting a special stem cell transplant, and later she showed signs of brain issues.
- Doctors figured out she had a weird condition called posterior reversible encephalopathy syndrome (PRES) after doing tests and scans.
- They stopped some of her medication, managed her blood pressure, gave her strong medicine, and after two weeks, her brain problems improved and tests showed she was getting better.
COVID-19 represented an important challenge to the Italian healthcare system (IHCS). Our main aim was to obtain evidence to support the use of modified national early warning score (m-NEWS) as an interdisciplinary, common, and universal scoring scale to quickly recognize patients with a risk of clinical deterioration before admission and during hospitalization. As a secondary goal, we tried to find a score threshold that can trigger patients' immediate medical review as a part of an optimal triaging protocol for an emergency setting where healthcare resources are overloaded.
View Article and Find Full Text PDF